» Articles » PMID: 30087774

The Impact of Within-host Ecology on the Fitness of a Drug-resistant Parasite

Overview
Specialty General Medicine
Date 2018 Aug 9
PMID 30087774
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The rate of evolution of drug resistance depends on the fitness of resistant pathogens. The fitness of resistant pathogens is reduced by competition with sensitive pathogens in untreated hosts and so enhanced by competitive release in drug-treated hosts. We set out to estimate the magnitude of those effects on a variety of fitness measures, hypothesizing that competitive suppression and competitive release would have larger impacts when resistance was rarer to begin with. We infected mice with varying densities of drug-resistant malaria parasites in a fixed density of drug-sensitive parasites and followed infection dynamics using strain-specific quantitative PCR. Competition with susceptible parasites reduced the absolute fitness of resistant parasites by 50-100%. Drug treatment increased the absolute fitness from 2- to >10 000-fold. The ecological context and choice of fitness measure was responsible for the wide variation in those estimates. Initial population growth rates poorly predicted parasite abundance and transmission probabilities. (i) The sensitivity of estimates of pathogen fitness to ecological context and choice of fitness measure make it difficult to derive field-relevant estimates of the fitness costs and benefits of resistance from experimental settings. (ii) Competitive suppression can be a key force preventing resistance from emerging when it is rare, as it is when it first arises. (iii) Drug treatment profoundly affects the fitness of resistance. Resistance evolution could be slowed by developing drug use policies that consider in-host competition.

Citing Articles

Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management.

Segovia X, Srivastava B, Serrato-Arroyo S, Guerrero A, Huijben S Malar J. 2025; 24(1):65.

PMID: 40025552 PMC: 11871665. DOI: 10.1186/s12936-025-05286-w.


Resistance Management for Cancer: Lessons from Farmers.

Seyedi S, Harris V, Kapsetaki S, Narayanan S, Saha D, Compton Z Cancer Res. 2024; 84(22):3715-3727.

PMID: 39356625 PMC: 11565176. DOI: 10.1158/0008-5472.CAN-23-3374.


Costs of antibiotic resistance genes depend on host strain and environment and can influence community composition.

Lai H, Cooper T Proc Biol Sci. 2024; 291(2025):20240735.

PMID: 38889784 PMC: 11285728. DOI: 10.1098/rspb.2024.0735.


Low Complexity of Infection Is Associated With Molecular Persistence of in Kenya and Tanzania.

Topazian H, Moser K, Ngasala B, Oluoch P, Forconi C, Mhamilawa L Front Epidemiol. 2024; 2:852237.

PMID: 38455314 PMC: 10910917. DOI: 10.3389/fepid.2022.852237.


Propensity of selecting mutant parasites for the antimalarial drug cabamiquine.

Stadler E, Maiga M, Friedrich L, Thathy V, Demarta-Gatsi C, Dara A Nat Commun. 2023; 14(1):5205.

PMID: 37626093 PMC: 10457284. DOI: 10.1038/s41467-023-40974-8.


References
1.
Vogwill T, MacLean R . The genetic basis of the fitness costs of antimicrobial resistance: a meta-analysis approach. Evol Appl. 2015; 8(3):284-95. PMC: 4380922. DOI: 10.1111/eva.12202. View

2.
Bell A, Blanford S, Jenkins N, Thomas M, Read A . Real-time quantitative PCR for analysis of candidate fungal biopesticides against malaria: technique validation and first applications. J Invertebr Pathol. 2009; 100(3):160-8. PMC: 2666797. DOI: 10.1016/j.jip.2009.01.006. View

3.
Gaibani P, Campoli C, Lewis R, Volpe S, Scaltriti E, Giannella M . In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018; 73(6):1525-1529. DOI: 10.1093/jac/dky082. View

4.
de Roode J, Culleton R, Bell A, Read A . Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Malar J. 2004; 3:33. PMC: 517944. DOI: 10.1186/1475-2875-3-33. View

5.
Roch M, Gagetti P, Davis J, Ceriana P, Errecalde L, Corso A . Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost. Front Microbiol. 2017; 8:2303. PMC: 5723333. DOI: 10.3389/fmicb.2017.02303. View